Collateral for a security interest recorded Feb 7, 2025 (Hayfin Services LLP).
Term ends Jun 25, 2030 · High confidence
20-year base term ends Jun 25, 2030
Held by Revance Therapeutics, Inc.
Filed Oct 30, 2018 as application 16/175,434 · Granted Jun 7, 2022
Base term, 20 years from filing
Today
2010
2030
Clock starts
Jun 25, 2010
Jun 25, 2010
Term ends
Jun 25, 2030
Jun 25, 2030
Granted
Jun 7, 2022
Jun 7, 2022
base term
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,111,939, to Jun 25, 2030. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 25, 2010, when application 12/824,118, the earliest non-provisional in its chain, was filed (this one was filed Oct 30, 2018) | Jun 25, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,111,939) | resolves to Jun 25, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 25, 2030 | High confidence |
This family
| US 9,340,587 | In force Sep 2035 | Sep 2035 |
| US 10,111,939 | In force Jun 2030 | Jun 2030 |
| US 11,351,232 | this patent Jun 2030 | Jun 2030 |
| US 11,911,449 | In force Jun 2030 | Jun 2030 |
| Application 18/414,311 | Pending not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 18, 2022 Reel 59437, frame 654 | Revance Therapeutics, Inc. | Athyrium Buffalo LP | Security Interest |
| Mar 18, 2022 Reel 59303, frame 446 | Thompson, Stewart A.; Ruegg, Curtis L.; Waugh, Jacob M. | Revance Therapeutics, Inc. | Assignment of Assignor's Interest |
| Feb 7, 2025 Reel 70153, frame 630 | Athyrium Buffalo LP | Revance Therapeutics, Inc. | Release of Security Interest |
| Feb 7, 2025 Reel 70153, frame 663 | Revance Therapeutics, Inc.; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 7, 2025 Reel 70153, frame 736 | Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 17, 2025 Reel 70239, frame 739 | Revance Therapeutics, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2030
Term ends Jun 25, 2030. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,111,939, ends no earlier than this term, so it caps nothing.
Citations
10
later US patents cite this one
That is top 25% of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.